Joe Ludwig (Queensland, Australian Labor Party, Manager of Government Business in the Senate) Share this | Hansard source

This is one of those areas where Senator Cormann needs to be able to distinguish between what we say are legitimate concerns and the misinformation that can arise. For example, despite claims to the contrary, patient safety will not be adversely affected by this measure, as it does not promote any change from current pharmacy practices in relation to the multiple use of chemotherapy phials. The government is reviewing the measure to ensure that patient treatment is not compromised and public and private oncology pharmacy services remain viable so that there will be no influx of patients from the private to the public sector. In taking on board the question that Senator Cormann asked, there are two matters that I have gone to: firstly, ensuring that patient safety will not be adversely affected, but also ensuring— (Time expired)